Second quarter (2024-10-01 – 2024-12-31)

• The Group's net sales amounted to SEK 0 (1,175).
• The Group's profit after financial items amounted to SEK -2,562,520 (946,531).
• Result per share amounted to SEK -0,16 (0.06).*

Six months (2024-07-01 – 2024-12-31)

• The Group's net sales amounted to SEK -4,965 (780,209).
• The Group's profit after financial items amounted to SEK -3,953,290 (-491,846).
• Result per share amounted to SEK -0,25 (-0.03).*
• The solidity as of 2024-12-31 was 7 (28%).**

* The Company’s result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of December 2024, amounted to 15,915,034 (15,220,000) shares. The result per share based on the average number of shares of 15,915,034  (15,220,000) amounts to SEK -0,25 (-0.03) for the six months 2024-07-01 to 2024-12-31.

** Solidity: Equity divided by total capital.

Highlights during the second quarter

• On October 30, 2024, the Board of Directors of ODI Pharma resolved to carry out an issue of shares with preferential right for the Company's existing shareholders. The decision is subject to approval at the Extraordinary General Meeting scheduled to be held on November 19, 2024. The issue volume amounts to a maximum of approximately SEK 4.1 million before transaction related costs. In the case of oversubscription ODI can also decide to utilize an over-allotment (the "Over-Allotment") to raise up to approximately additionally SEK 2.0 million through the rights issue. The decision on the Rights Issue is secured via pre-subscription in writing by Volker Wiederrich and the existing shareholder Niclas Kappelin to a total of approximately 49 percent.
• On October 30, 2024, ODI proposed to elect Malcolm Allan as new member of the Board of Directs of ODI Pharma at the extraordinary general meeting on November 19, 2024.
• On November 12, 2024, ODI announced the appointment of Jan-Mark Edewaard as the new CEO of ODI as of January 1, 2025. Current CEO, Derek Simmross, will remain in his role until January 1, 2025.
• On December 4, 2024, ODI provided an update on Poland's expanding medical cannabis market, which remains an important focus of the Company's strategy. Recent regulatory changes in Poland highlight ODI's established position in one of Europe's most promising markets for medical cannabis.
• On December 11, 2024, ODI announced outcome of the rights issue. The Rights Issue was subscribed to a total of approximately 54.8 percent, including pre-subscription commitments. ODI will thus be provided proceeds of approximately SEK 2.2 million before deduction of transaction related costs.
•  On December 13, ODI informed that that the current CEO, Derek Simmross, did not subscribe to his pro-rata in the completed rights issue in ODI Pharma and has therefore fallen below the threshold of 25 percent.  After the transaction, Derek's holdings amount to the same amount of shares, 3,950,000, however equivalent to approximately 24,82% of the voting and capital share in the company.

Highlights after the end of the period

• On January 16, 2025, ODI announced the termination of the agreement regarding the liquidity provider with Pareto Securities AB. The last day for the service of liquidity support by Pareto is March 14, 2025. 

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com  

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.